Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-19
2005-04-19
Nguyen, Dave Trong (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C530S350000
Reexamination Certificate
active
06881724
ABSTRACT:
Described is the use of magnesium (Mg2+) for the preparation of a therapeutic composition for the introduction of a polynucleotide into a cell in vivo.
REFERENCES:
patent: 4798789 (1989-01-01), Lee et al.
patent: 5593972 (1997-01-01), Weiner
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5831048 (1998-11-01), Schweighoffer
patent: 5844107 (1998-12-01), Hanson
patent: 5958684 (1999-09-01), Van Leeuwen et al.
patent: 5998144 (1999-12-01), Reff et al.
patent: 6143518 (2000-11-01), Cameron et al.
patent: 6258791 (2001-07-01), Braun
patent: 6528312 (2003-03-01), Braun
patent: 6544523 (2003-04-01), Chu
Rosenecker (Eur. J. Med. 23(3): 149-156, Mar. 1998.*
Boucher (J. Clin. Invest. 103(4): 441-445 Feb. 1999).*
Davies (Mol. Med Today 4(7): 292-299, Jul. 1998, p. 294, column 2, lines 20-28).*
Alton and Geddes (J. R. Soc. Med 90 Suppl 31: 43-46 1997).*
Boucher (TIG 1.2(3): 81-84, 1996, p. 81, paragraph bridging columns 2 and 3).*
McCluskie et al (Molecular Medicine 5(5): 287-300, 1999).*
Chattergoon et al (FASEB J. 11: 753-763, 1997).*
Karpati et al (Clin. Invest. Med. 17(5): 499-509, 1994).*
Rosenfeld and Collins (Chest 109:241-252, 1996).*
Verma et al (Nature 389: 239-242, 1997).*
Somia and Verma (Nature Reviews Genetics 1: 91-99, 2000).*
Romano et al (Stem Cells 18: 19-39, 2000).*
Anderson (Nature 392:25-30, 1998).*
Derwent Abstract, XP-002099637, “Introducing Gene Cell Virus Serum Serum Free Ingredient Cell Culture Medium Based Aminoacid,” Nov. 26, 1996.
Derwent Abstract, XP-002099636, “Cyclic DNA Transductor Acetic Acid Bacteria Solution Contain One More Magnesium Calcium Strontium Barium Manganese,” Sep. 25, 1985.
Wells et al., “Evaluation of Plasmid DNA for in Vivo Gene Therapy: Factors Affecting the Number of Transfected Fibers,”Journal of Pharmaceutical Sciences, 1998, pp. 763-768, vol. 87, No. 6, John Wiley & Sons, New York, New York.
Garcia et al., “Early Stages inBacillus subtilisTransformation: Association Between Homologous DNA and Surface Structures,”Journal of Bacteriology, 1978, pp. 731-740, vol. 135, No. 3, American Society for Microbiology, Washington, D.C.
Verma et al., “Gene therapy—promises, problems and prospects,”Nature, 1997, pp. 239-242, vol. 389, Nature Publishing Group, England.
Ledley, “Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products,”Human Gene Therapy, 1995, pp. 1129-1144, vol.6, Mary Ann Liebert, Inc., Larchmont, New York.
Svinarchuk et al., “A New approach to overcome potassium-mediated inhibition of triplex formation,”Nucleic Acids Research, 1996, pp. 3858-3865, vol. 24, No. 19, Oxford University Press, Oxford, UK.
Association Francaise Contre les Myopathies
Burns Doane Swecker & Mathis L.L.P.
Nguyen Dave Trong
Schnizer Richard
Transgene S.A.
LandOfFree
Use of magnesium (Mg2+) for the preparation of a therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of magnesium (Mg2+) for the preparation of a therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of magnesium (Mg2+) for the preparation of a therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3370823